Interestingly, genomic analysis of available precancerous lesions from baseline and end-of-study colonoscopies showed a trend toward reduced frequency of MSI precancers after vaccine exposure, in line with the mechanism of action of Nous-209 targeting frameshift mutations occurring as a consequence of the impairment of the MMR system.
← all excerpts
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
1
—
—